Raltitrexed
- Generic Name
- Raltitrexed
- Brand Names
- Tomudex
- Drug Type
- Small Molecule
- Chemical Formula
- C21H22N4O6S
- CAS Number
- 112887-68-0
- Unique Ingredient Identifier
- FCB9EGG971
- Background
Raltitrexed (brand name Tomudex®) is a chemotherapy drug manufactured AstraZeneca Company, is an antimetabolite used in chemotherapy. It is an inhibitor of thymidylate synthase.
- Indication
For the treatment of malignant neoplasm of colon and rectum
- Associated Conditions
- Advanced Colorectal Cancer, Pleural Mesotheliomas
- Associated Therapies
- -
A Phase-II Study Of Raltitrexed/Oxaliplatin Plus Radiotherapy Versus Radiotherapy In Subjects With Inoperable Esophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-11-22
- Last Posted Date
- 2012-11-22
- Lead Sponsor
- The First People's Hospital of Lianyungang
- Target Recruit Count
- 108
- Registration Number
- NCT01732380
- Locations
- 🇨🇳
The First People's Hospital of Lianyungang, Lianyungang, Jiangsu, China
Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-11-29
- Last Posted Date
- 2021-02-03
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 62
- Registration Number
- NCT01481545
Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Standard Chemotherapy in Unresectable Liver Metastases From Colorectal Cancer After Conventional Chemotherapy Failure
- Conditions
- Interventions
- First Posted Date
- 2011-05-05
- Last Posted Date
- 2018-07-16
- Lead Sponsor
- Centre Georges Francois Leclerc
- Target Recruit Count
- 31
- Registration Number
- NCT01348412
- Locations
- 🇫🇷
Centre Georges François Leclerc, Dijon, France
A Phase-II Study Of TOMUDEX Plus Radiotherapy In Subject With Inoperable or Recurrent Rectal Cancer
- Conditions
- First Posted Date
- 2008-01-10
- Last Posted Date
- 2008-01-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 49
- Registration Number
- NCT00590278
- Locations
- 🇹🇷
Research Site, Istanbul, Turkey
Irinotecan Plus Raltitrexed in Treating Patients With Refractory Solid Tumors
- Conditions
- First Posted Date
- 2004-07-08
- Last Posted Date
- 2013-04-17
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 39
- Registration Number
- NCT00003109
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Irinotecan Plus ICI D1694 in Treating Patients With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2004-05-24
- Last Posted Date
- 2019-03-13
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Registration Number
- NCT00002902
- Locations
- 🇺🇸
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States
Palliative Chemotherapy in Treating Patients With Advanced Colorectal Cancer
- Conditions
- First Posted Date
- 2004-05-13
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Medical Research Council
- Target Recruit Count
- 900
- Registration Number
- NCT00002893
- Locations
- 🇬🇧
Velindre Hospital, Cardiff, Wales, United Kingdom
Raltitrexed in Treating Patients With Malignant Mesothelioma That Cannot Be Surgically Removed
- Conditions
- First Posted Date
- 2004-04-23
- Last Posted Date
- 2012-07-18
- Target Recruit Count
- 25
- Registration Number
- NCT00004254
- Locations
- 🇳🇱
Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands
🇮🇹Ospedale Bellaria, Bologna, Italy
🇮🇹Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Raltitrexed in Treating Children With Refractory Acute Leukemia
- Conditions
- Interventions
- First Posted Date
- 2004-03-01
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00003528
- Locations
- 🇨🇭
Swiss Pediatric Oncology Group - Geneva, Geneva, Switzerland
Chemotherapy With Raltitrexed and Fluorouracil in Treating Patients With Advanced Colorectal Cancer
- Conditions
- First Posted Date
- 2003-11-24
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00002828
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.